Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have characterized a high-affinity [35S]-glutathione ([35S]
GSH
) binding site in mouse and human spinal cord. [35S]
GSH
binding sites in mouse and human spinal cord were observed largely within the gray matter in both the dorsal and ventral horns of spinal cord at cervical, thoracic, and lumbosacral segments. High-affinity [35S]
GSH
binding was saturable, showing a Bmax of 72 fmol/mg of protein and a KD of 3.0 nM for mouse spinal cord and a Bmax of 52 fmol/mg of protein and a KD of 1.6 nM for human spinal cord. [35S]
GSH
binding was displaceable by
GSH
, L-cysteine, and S-hexyl-
GSH
, but not by glutamate, glycine, or NMDA. These [35S]
GSH
binding sites exhibited kinetic and saturation characteristics similar to
GSH
binding sites in rat brain astrocytes. To determine whether [35S]
GSH
binding sites could be regulated by
protein kinase C
, we exposed human spinal cord sections to phorbol 12,13-diacetate for 1 h before ligand binding. Phorbol ester treatment increased [35S]
GSH
binding by approximately 60%, an effect that could be blocked by exposure of spinal cord sections to 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, a general protein kinase inhibitor. [35S]
GSH
binding sites in the spinal cord of both species exhibited many of the characteristics of a receptor including saturable binding, high affinity, ligand specificity, and modulation by kinase activity. These data suggest that
GSH
is a neurotransmitter in the CNS.
...
PMID:Characterization, distribution, and protein kinase C-mediated regulation of [35S]glutathione binding sites in mouse and human spinal cord. 820 24
Vasopressin stimulated
GSH
efflux from Hep G2 cells. The maximal effect was observed at 10nM. Pretreatment with pertussis toxin or cholera toxin for 18 hr increased
GSH
efflux. Vasopressin-mediated
GSH
efflux was observed even in the cells pretreated with those compounds. Dibutyryl-cAMP or dibutyryl-cGMP enhanced
GSH
efflux although an additive effect of vasopressin was not observed. Glucagon and a phorbol ester independently increased
GSH
efflux while both compounds decreased the effect of vasopressin. Staurosporine, an inhibitor of
protein kinase C
, inhibited vasopressin-mediated
GSH
efflux. The effect of vasopressin was observed even in the absence of extracellular Ca2+. Vasopressin stimulates
GSH
efflux from Hep G2 cells and
protein kinase C
-dependent pathway may play a significant role in vasopressin-mediated
GSH
efflux.
...
PMID:Characterization of vasopressin-mediated GSH efflux from Hep G2 cells: significance of protein kinase C. 845 Jul 14
HeLa cells were treated once or repeatedly using the cytostatics doxorubicin (adriamycin, Ad, CAS 23214-92-8), cisplatin (Pt, CAS 15663-27-1) and fluorouracil (FU, CAS 51-21-8). Intracellular
GSH
(reduced glutathione) contents, activities of
protein kinase C
, cytotoxicity and membrane fluidity were investigated. During single treatment
protein kinase C
activities as well as membrane fluidity increased, whereas intracellular
GSH
decreased. With repeated treatments
protein kinase C
activities increased further. Membrane fluidity as well as intracellular
GSH
contents increased. The investigated parameters may be correlated with sensitivity of cells against cytostatics.
...
PMID:Intracellular changes of HeLa cells after single or repeated treatment with cytostatics. 848 70
We have investigated in Ehrlich-ascites-tumour-bearing mice the effect of buthionine sulphoximine (BSO), a selective inhibitor of
GSH
synthesis, on the rate of
GSH
depletion of tumour versus normal tissues and its relation to tumour cell proliferation. In normal tissues,
GSH
and GSSG remain unchanged or close to normal values during tumour growth, even at the last stage of growth when the animal is close to death. After administration of a single dose of BSO (4 mmol/kg), the rates of
GSH
depletion and recovery in the tumour and in several normal tissues are very different. BSO depletes
GSH
in cancer cells to a level of 0.3-0.4 mumol/g. The fall in
GSH
levels is faster when tumour cells do not proliferate actively. Four treatments of 4 mmol of BSO/kg at 48 h intervals induce a significant decrease (about 44%) in tumour growth. Our data show that the rate of BSO-induced
GSH
depletion in cancer cells depends on the stage of tumour growth, and that BSO administration also inhibits cancer-cell proliferation. A mechanism involving changes in
protein kinase C
activity and intracellular pH is proposed to explain the inhibition of cancer growth elicited by BSO.
...
PMID:Depletion of tumour glutathione in vivo by buthionine sulphoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth. 850 82
Administration of high doses (150-250 mg/kg body weight) of phenytoin (DPH) promote a 40% decrease in glutathione (
GSH
) content of rat sciatic nerve. This DPH-induced
GSH
depletion is accompanied with an electrophysiological impairment of peripheral neuromuscular function. H7 (20 mg/kg body weight IP, 30 min prior to DPH), a protein kinase C inhibitor, was able to prevent the DPH-induced
GSH
depletion only at the lower DPH dose used. This same inhibitor completely prevented the electrophysiological impairment at the lower DPH dose, and only partially at the higher DPH dose used. These results confirm the hypothesis of a DPH-dependent activation of
PKC
(that might be triggered by, or be the consequence of, the reduction of the intracellular antioxidant
GSH
), as one of the pathophysiological mechanisms involved in DPH-induced neurotoxicity.
...
PMID:Phenytoin-induced glutathione depletion in rat peripheral nerve. 852 26
The present study explores a model for tumor cell-induced immunosuppression and reversal of suppression by cytokines and other pharmacological agents. To simulate tumor-cell-induced suppression, a panel of suppressor agents which included CsA (cyclosporin A), SSP (staurosporine), BSO (L-buthionine-[S,R]-sulfoximine) and PMA, and a panel of anti-suppressor agents which included IL-2, IL-4,
GSH
(glutathione) and amiloride, were tested. These suppressor/anti-suppressor agents acted differently on four specific sites of the immune arm that affected the alpha CD3-induced T cell proliferative and cytotoxic responses. They included (1) IL-2 production, (2)
PKC
-regulated cytolytic granule production, (3)
GSH
-regulated maturation of functional granules, and (4) granule exocytosis. When a single suppressor agent was used, all the suppressor agents tested in this study inhibited the generation of alpha CD3-induced activated killer cells (CD3-AK), whereas alpha CD3-induced proliferation was inhibited by CsA, BSO, and EL-4 tumor cells. Except for EL-4, suppression induced by a single suppressor agent could be corrected by an appropriate single anti-suppressor agent. Multiple suppressor agents induced profound suppression of CD3-AK response. In most cases, multiple anti-suppressor agents were required to correct the immune defects induced by multiple suppressor agents. Finally, EL-4 tumor-cell-induced immunosuppression could not be corrected by any single anti-suppressor agent tested, but a combination of IL-4,
GSH
and amiloride fully restored the CD3-AK response. These results suggest that tumor cells may induce multiple immune defects that require multiple anti-suppressor agents for correcting the defects to restore the host immunocompetence.
...
PMID:Reversal of multiple-site tumor cell-induced immunosuppression by specific cytokines and pharmacological agents. 853 Feb 53
The effect of n-3 and n-6 fatty acids (FAs) on the growth of human cervical carcinoma (HeLa) cells was studied. Of all the FAs tested, docosahexaenoic acid (DHA, 22:6 n-3) and eicosapentaenoic acid (EPA, 20:5 n-3) were found to be the most potent in their cytotoxic action on HeLa cells and the potency of various fatty acids with regard to their cytotoxic action was as follows: DHA > EPA > dihomo-gamma-linolenic acid (DGLA) = gamma-linolenic acid (GLA) > linoleic acid (LA) > arachidonic acid (AA) > alpha-linolenic acid (ALA). The cycloxygenase inhibitor indomethacin, the lipoxygenase inhibitor nordihydroguaretic acid (NDGA), the antioxidants vitamin E, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT), the superoxide anion quencher superoxide dismutase (SOD), the hydroxyl and hydrogen peroxide quenchers mannitol and catalase, respectively, and the calmodulin antagonists trifluoperazine (TFP) and chlorpromazine (CPZ) could all block the cytotoxic action of GLA, which was used as a representative cytotoxic FA, on HeLa cells. On the other hand, copper and iron salts and buthionine sulfoxamine, a glutathione (
GSH
) depletor, potentiated the cytotoxic action of suboptimal doses of GLA. GLA-induced radical generation and lipid peroxidation in HeLa cells could be blocked by indomethacin, NDGA and calmodulin antagonists. The cytotoxic action of cis-unsaturated fatty acids (c-UFAs) is not dependent on the alteration in the
protein kinase C
levels since no alteration in the diacylglycerol levels was observed. Hydroxy and hydroperoxy products of GLA were found to be toxic to HeLa cells, whereas prostaglandin (PG)E1, PGF2 alpha, and prostacyclin stimulated cell growth. From these results, it is evident that radicals are the modulators of the cytotoxic action of c-UFAs, that their formation is a calmodulin-dependent process, and that lipoxygenase products may mediate the tumoricidal action of FAs.
...
PMID:Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells in vitro. 857 83
We investigated the effects of proximal modulators of cytokines, tyrosine kinase (TK), and
protein kinase C
(
PKC
) on reactive oxygen species (ROS) generation and the induction of scavenging enzymes, superoxide dismutase (SOD), catalase, and glutathione peroxidase (
GSH
-Px) of human neutrophils and lymphocytes, by using IL1-alpha, TNF-alpha, and IFN-gamma and neutralizing antibodies to these cytokines. Inhibitors of TK (ST638 and herbimycin) or
PKC
(H-7, calphostin, and staurosporine) were also used. The results revealed that both (O2)- generation stimulated by five different agents (opsonized zymosan, A23187, PAF, PMA, and fMLP) and the inductions of all three scavenging enzymes were potentiated by priming with TNF-alpha. In contrast, both (O2)- generation and enzyme induction were attenuated by priming with IL1-alpha, with the exception of PMA-stimulated (O2)- generation. IFN-gamma decreased (O2)- generation but increased scavenging enzyme induction. Antibodies to all three cytokines and all the TK and
PKC
inhibitors decreased (O2)- stimulated by most agents, but markedly enhanced (O2)- levels stimulated by PAF. Induction of all three enzymes was enhanced equally by low concentrations of each of the three anticytokine antibodies, while each of the TK or
PKC
inhibitors decreased induction of SOD and
GSH
-Px and increased catalase induction. These results suggest that both ROS generation and scavenging enzyme induction are controlled in complex ways by the actions of these three proximal mediators. This supports our hypothesis that disturbances in the regulation of early events of cell activation can lead to oxidative tissue injury.
...
PMID:Role of cytokines, tyrosine kinase, and protein kinase C on production of superoxide and induction of scavenging enzymes in human leukocytes. 863 90
Leukotriene C4 synthase (EC 2.5.1.37) catalyzes the conjugation of reduced glutathione (
GSH
) with leukotriene A4 to form the intracellular parent of the proinflammatory cysteinyl leukotrienes. Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds. We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence. Mouse leukotriene C4 synthase cDNA is 667 bp in length, including the poly(A)-rich tail, and shows 87% similarity with the human cDNA within the open reading frame. The deduced 150-amino-acid sequence of mouse leukotriene C4 synthase (differs from the human enzyme by only 18 amino acids, of which 9 reside at the C terminus. The potential N-glycosylation site, two
protein kinase C
phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase. Northern blot analysis indicated that the leukotriene C4 synthase RNA transcript is widely distributed. The Km values for leukotriene A4 methyl ester, leukotriene A4 free acid and
GSH
were 7.6 microM, 3.6 microM and 1.6 mM, respectively, for purified human recombinant enzyme, and 10.3 microM, 2.5 microM and 1.9 microM, respectively, for purified recombinant mouse enzyme; the corresponding Vmax values were 2.5, 1.3 and 2.7 micromol x min(-1) x mg(-1) protein, respectively, for human enzyme, and 2.3, 1.2 and 2.2 micromol x min(-1) x mg(-1) protein, respectively, for mouse enzyme. The 5-lipoxygenase-activating-protein inhibitor, MK-886, was active against both human and mouse recombinant leukotriene C4 synthase with IC50 values of 3.1 microM and 2.7 microM respectively. These findings confirm that the leukotriene C4 synthases belong to a gene family that includes the 5-lypoxygenase-activating protein and suggest that the C-terminal domain of leukotriene C4 synthase may not be critical for its conjugation function.
...
PMID:Molecular cloning, expression and characterization of mouse leukotriene C4 synthase. 870 58
Oxidative stress and antioxidants have been related in a wide variety of ways with nervous tissue. This review attempts to gather the most relevant information related to a) the antioxidant status in non pathologic nervous tissue; b) the hypothesis and evidence for oxidative stress (considered as the disequilibrium between prooxidants and antioxidants in the cell) as the responsible mechanism of diverse neurological diseases; and c) the correlation between antioxidant alterations and neural function, in different experimental neuropathies. Decreased antioxidant availability has been observed in different neurological disorders in the central nervous system, for example, Parkinson's disease, Alzheimer's disease, epilepsy, amyotrophic lateral sclerosis, cerebral ischaemia, etc. Moreover, the experimental manipulation of the antioxidant defense has led in some cases to interesting experimental models in which electrophysiological alterations are associated with the metabolic modifications induced. In view of the electrophysiological and biochemical effects of some
protein kinase C
inhibitors on different neural experimental models, special attention is dedicated to the role of this kinase in peripheral nervous tissue. The nervous tissue, central as well as peripheral, has two main special features that are certainly related to its antioxidant metabolism: the lipid-enriched membrane and myelin sheaths, and cellular excitability. The former explains the importance of the glutathione (
GSH
)-conjugating activity towards 4-hydroxy-nonenal, a biologically active product of lipid peroxidation, present in nervous tissue and in charge of its inactivation. The impairment of the latter by oxidative damage or experimental manipulation of antioxidant metabolism is discussed. Work on different experimental neuropathies from author's laboratory has been primarily used to provide information about the involvement of free radical damage and antioxidants in peripheral nerve metabolic and functional impairment.
...
PMID:Antioxidants in peripheral nerve. 874 79
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>